OVI-586

Granata Bio Corporation, a biopharma company focused on invigorating the $3.6B global infertility medication market, has today announced the acquisition of Oviva Therapeutics, a U.S.-based biotech focused on female reproductive longevity. Oviva’s flagship asset, OVI-586, is described as a first-in-class therapy aimed at extending ovarian function - potentially redefining how the health span of women is understood and treated. Designed to address one of the earliest hallmarks of biological aging - the decline of the ovaries - OVI-586 could have applications across menopause, contraception, and IVF. “This is a big day for women’s health,” said James Peyer, Founder and CEO of Cambrian BioPharma, which co-founded Oviva alongside scientists Drs. Daisy Robinton, David Pepin, and Pat Donahue. “Cambrian partnered […] to found Oviva and develop the first truly novel mechanism in women's health in the last 50 years. We're thrilled about this acquisition and looking forward to seeing Oviva's OVI-586 progress to the next stage of development under Granata's leadership. This transaction reflects the importance of Cambrian's objective: identify amazing scientific discoveries and turn those discoveries into great businesses.” The acquisition is strategic expansion for Granata Bio, which has carved out a niche in fertility and assisted reproductive technologies since its founding in 2018. The company has a big goal to reduce the cost of IVF medications - its says that the price of IVF medications has increased by 50% since 2014 and fertility insurance coverage in the US is still patchy meaning patients often bear the costs themselves or cannot afford fertility treatments altogether. In January, Granata Bio secured a $15million Series A+ to further its medication pipeline.